TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28689524
Drug: Supervised Structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan
Study: 29171557
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication and dietary plan
Study: 18773134
Drug: Vaginal vault
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal vault suspension after hysterectomy (n = 32)
Study: 12950574
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (CG), coronally unsealed
Study: 12950574
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide + 2% chlorhexidine gel (CaOH2 + CG), coronally unsealed
Study: 12950574
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (CG) + coronal seal
Study: 12950574
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide + 2% chlorhexidine gel (CG + CaOH2) + coronal seal
Study: 12950574
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control group (PC) - no treatment, coronally unsealed
Study: 8723171
Drug: Pranidipine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranidipine 1 mg od
Study: 8723171
Drug: Pranidipine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranidipine 2 mg od
Study: 8723171
Drug: Pranidipine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranidipine 4 mg od
Study: 8723171
Drug: Pranidipine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranidipine 8 mg od
Study: 1362887
Drug: L-659,066 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-659,066 (8 mg administered by short intravenous infusion)
Study: 3907286
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for one month
Study: 10874063
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for six months
Study: 27676396
Drug: 0 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/d CAP from chili powder
Study: 27676396
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d CAP from chili powder
Study: 27676396
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d CAP from chili powder
Study: 12425363
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (btA) injection with conventional physical therapy
Study: 8610920
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer treatment in black women
Study: 1356277
Drug: Alpidem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (mean dose 112.5 mg daily)
Study: 1356277
Drug: Lorazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (mean 3.5 mg daily)
Study: 3895962
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment with 500 mg clotrimazole vaginal tablet
Study: 3895962
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with two 100 mg vaginal tablets administered daily
Study: 20497921
Drug: Standard support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard support therapy (ST)
Study: 16178478
Drug: Glucose-only-based solutions
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-only-based solutions
Study: 12546607
Drug: Diclofenac sodium,
Normalized name: diclofenac sodium, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium, 75 mg twice daily
Study: 12546607
Drug: Acetaminophen, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 1000 mg 4 times daily
Study: 7561223
Drug: 8-hourly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-hourly administration of controlled-release morphine (MS Contin)
Study: 7561223
Drug: 12-hourly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-hourly administration of controlled-release morphine (MS Contin)
Study: 7561223
Drug: 8-hourly and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hourly and 12-hourly administration of controlled-release morphine (MS Contin)
Study: 1782724
Drug: Control (unchanged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unchanged EPO prescription)
Study: 31611496
Drug: Acidic solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic solution, pH 1-2 (CS)
Study: 31611496
Drug: Alkaline solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline solution, pH 10-11 (KS)
Study: 28597306
Drug: Etanercept-methotrexate combination
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept-methotrexate combination therapy
Study: 28597306
Drug: Placebo-methotrexate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-methotrexate combination therapy
Study: 21424238
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (prednisolone 0.5%)
Study: 21424238
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment duration
Study: 19894007
Drug: Pulsed signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed signal therapy
Study: 17362810
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once daily for 7 days
Study: 17362810
Drug: Amoxicillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days
Study: 11210396
Drug: NN703 (growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (growth hormone secretagogue) administered po as a solution, dose levels: 8, with 6 subjects on active treatment per dose level.
Study: 11210396
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group), 2 subjects per dose level.
Study: 9553909
Drug: Low-dose etretinate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etretinate therapy
Study: 31834814
Drug: Daily running
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily running exercise for 7 days
Study: 31379058
Drug: Tenofovir or
Normalized name: emtricitabine/nelfinavir/tenofovir oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir or adefovir treatment for 4 years
Study: 27851857
Drug: Eravacycline, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline, 1.0 mg/kg every 12 hours for a minimum of four 24-hour dosing cycles
Study: 27851857
Drug: Ertapenem, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem, 1.0 g every 24 hours for a minimum of four 24-hour dosing cycles
Study: 25611803
Drug: Mometasone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone (400 μg)
Study: 25611803
Drug: Mometasone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone (400 μg) administered 30 min before albuterol
Study: 25611803
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 30 min before albuterol
Study: 25739188
Drug: Remaxol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol (intravenous drip, 400 ml per day, 10 days)
Study: 25739188
Drug: Essentiale N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essentiale N (intravenous bolus, 5 ml per day, 10 days)
Study: 17585221
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg etanercept intradiscally
Study: 17585221
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg etanercept intradiscally
Study: 17585221
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg etanercept intradiscally
Study: 17585221
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg etanercept intradiscally
Study: 17585221
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg etanercept intradiscally
Study: 17585221
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg etanercept intradiscally
Study: 9704955
Drug: PolyHeme (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyHeme (up to 6 U, 300 g)
Study: 25738481
Drug: ACEI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI-based treatment (enalapril)
Study: 25738481
Drug: Diuretic-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-based treatment (hydrochlorothiazide)
Study: 21198801
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection technique (not changing the needle)
Study: 16433809
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% in thermophobic foam (CF) applied twice daily
Study: 9051539
Drug: Oral-transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-transdermal clonidine regimen (4 to 5 mu/kg oral clonidine and 0.2 mg/24 hours transdermal patch)
Study: 9051539
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet and patch
Study: 9051539
Drug: Oral-transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-transdermal clonidine regimen
Study: 26447154
Drug: d6-RRR-α-tocopherol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d6-RRR-α-tocopherol (15 mg) with nonfat milk (0.2 g fat)
Study: 26447154
Drug: d6-RRR-α-tocopherol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d6-RRR-α-tocopherol (15 mg) with reduced-fat milk (4.8 g fat)
Study: 26447154
Drug: d6-RRR-α-tocopherol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d6-RRR-α-tocopherol (15 mg) with whole milk (7.9 g fat)
Study: 23233252
Drug: Topical pazopanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pazopanib 0.5% for 3 weeks
Study: 16496249
Drug: Dorzolamide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide + Timolol Fixed Combination (DTFC)
Study: 10699771
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with meperidine as additional analgesia, self-administered by patients.
Study: 10699771
Drug: Standard sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sedation with meperidine and midazolam administered by the anesthesiologist.
Study: 8408793
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate (MPA) 0.1% ointment
Study: 8408793
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate ointment
Study: 2960897
Drug: t-PA (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-PA (80 to 100 mg intravenously over three hours)
Study: 25602175
Drug: Ranolazine 375
Normalized name: Ranolazine 375 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 375 mg bid
Study: 20828645
Drug: Ranolazine 500
Normalized name: ranolazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 500 mg bid
Study: 25602175
Drug: Ranolazine 750
Normalized name: Ranolazine 750 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 750 mg bid
Study: 25602175
Drug: Combined ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ranolazine 500 mg and 750 mg
Study: 20001868
Drug: Dienogest (DNG)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest (DNG) 2 mg/day
Study: 20001868
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate
Study: 20001868
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 10 mg/day
Study: 16893642
Drug: Conventionally dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally dosed chemotherapy (group A)
Study: 10460994
Drug: 17alpha-hydroxyprogesterone caproate
Normalized name: 17alpha-Hydroxyprogesterone hexanoate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17alpha-hydroxyprogesterone caproate (17-OHPc) at a dosage of 341 mg every 3 days
Study: 10460994
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo every 3 days
Study: 31957794
Drug: Telephone outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone outreach call plus invitation to engage in mental health tailored telephone counseling and assistance obtaining nicotine replacement therapy
Study: 31421395
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (136.6 mg aglycone equivalence)
Study: 20566178
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment based on severity: OSDI (mild) = carboxymethylcelullose, OSDI (moderate) = hidroxypropylmethylcelullose, OSDI (severe) = polyethyleneglycol, OSDI (very severe) = polyethyleneglycol + cyclosporine A 0.05%.
Study: 20566178
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment administered based on severity of symptoms.
Study: 12028164
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 4 mg once daily (n = 507)
Study: 10215688
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg/kg combined with midazolam 0.05 mg/kg
Study: 10215688
Drug: Pethidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 1.0 mg/kg
Study: 10215688
Drug: Ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine hydrochloride 4.0 mg/kg (oral)
Study: 10215688
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (oral)
Study: 8570775
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) at a daily oral dose of 0.5 mg/kg/day
Study: 2223424
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of carbamazepine
Study: 2223424
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with zopiclone and carbamazepine
Study: 453259
Drug: Laminaria placed
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria placed at the time of the abortifacient injection (Group II, N = 23)
Study: 453259
Drug: Laminaria placed
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria placed 4 hours prior to injection (Group III, N = 29)
Study: 453259
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (Group I, N = 28)
Study: 31838255
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (110 ≤ SBP < 130 mmHg)
Study: 31838255
Drug: Mild treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild treatment (130 ≤ SBP < 150 mmHg)
Study: 26175420
Drug: Antiosteoporotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiosteoporotic drugs
Study: 16881774
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for bipolar disorder (duration up to 28 months)
Study: 11260171
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg of zinc sulphate orally
Study: 11260171
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of zinc sulphate orally
Study: 11260171
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of zinc sulphate orally
Study: 8427168
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg 3 times daily
Study: 29921575
Drug: Shen-Shuai-Ning (SSN)
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen-Shuai-Ning (SSN) granule, 5 g three times daily for 12 weeks
Study: 29921575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (baseline medications and dialysis prescriptions)
Study: 26162647
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 5 mg/kg
Study: 24613110
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human interleukin 11, 1.5 mg subcutaneously
Study: 20378829
Drug: TU-100 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 2.5 g tid
Study: 20378829
Drug: TU-100 5
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 5 g tid
Study: 20378829
Drug: TU-100 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 7.5 g/day
Study: 12625641
Drug: Treadmill therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treadmill therapy with partial body weight support (BWS)
Study: 22394493
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Group Therapy (CBGT); 12-session protocol
Study: 18853113
Drug: Shugan Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jianpi Granule (SJG) 24 g three times a day
Study: 18853113
Drug: Shugan Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Jianpi Granule (SJG) 24 g three times a day + Smecta 15 g three times a day
Study: 16447880
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng injection (SFI) 100 ml, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Study: 16447880
Drug: Nitroglycerine injection
Normalized name: nitroglycerin Injection
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine injection 10 mg, administered in 5% glucose solution 500 ml for intravenous dripping, once a day for 20 days
Study: 7750591
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (10 mg/d)
Study: 7857113
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of strong sunscreen
Study: 7049029
Drug: Tetracycline hydrochloride,
Normalized name: Tetracycline Hydrochloride, Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline hydrochloride, 500 mg orally four times daily for 7 days
Study: 7049029
Drug: Rosaramicin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosaramicin, 250 mg orally four times daily for 7 days
Study: 31257264
Drug: MFGM 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM 1.0 g + glucosamine 1.5 g
Study: 26262771
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg
Study: 26262771
Drug: Eplerenone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (all doses)
Study: 26262771
Drug: Eplerenone (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (multiple doses)
Study: 25249056
Drug: Small Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Group (SG) treatment (12 members/group)
Study: 25249056
Drug: Large Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large Group (LG) treatment (30 members/group)
Study: 19691545
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive‐behavior therapy (CBT)
Study: 15190831
Drug: Viagra combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra combined with behavior therapy
Study: 15190831
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy alone (control group)
Study: 7741071
Drug: DES (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (500 mg daily injection) for 7 days before LH-RH analogue (3.6 mg of Zoladex depot)
Study: 7741071
Drug: DES (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 7 days
Study: 7741071
Drug: DES (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (500 mg injection) for 7 days simultaneously with LH-RH analogue
Study: 7741071
Drug: DES (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (500 mg injection) for 7 days prior to LH-RH analogue, plus additional DES injection for 3 days
Study: 1970298
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg daily (increased to 20 mg if necessary)
Study: 1970298
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily (increased to 100 mg if necessary)
Study: 31775686
Drug: Sulfadoxine-Pyrimethamine (IPTp-SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-Pyrimethamine (IPTp-SP) administered during pregnancy